IDCRC Newsletter: January 2024

IDCRC Investigator Profile: Jodie Dionne, MD, MSPH

Spotlight: Saint Louis University Site Visit

The IDCRC Leadership Group (LG) continues their Vaccine and Treatment Evaluation Units (VTEU) site visits. On November 17, 2023, IDCRC PIs, David Stephens, MD, Kathy Neuzil, MD, and Clinical Operations Unit co-director, Jeff Lennox, MD, visited the Saint Louis University (SLU) VTEU.

“It was an absolute pleasure to visit the SLU site and to learn about their scientific and public health accomplishments. The high regard with which they are held at the School of Medicine, the university, and the broader community was evident in our many interactions throughout the day,” says Neuzil.

The Leadership Group thanks the Saint Louis University VTEU again for their hospitality and looks forward to visiting again soon.

Annual Award Nominations

Nominations are now open for the 2024 Annual IDCRC Awards

The IDCRC presents annual awards to acknowledge the work of VTEU members who have made exceptional contributions to the IDCRC and VTEU missions. We are now taking nominations for 2024. Nominations can be made by any IDCRC LG or VTEU member. Nominators may submit a nomination for each award category. 

All nominations must be received by Friday, March 1, 2024. 

Award Nomination Categories: 

• Investigator of the Year: A well-established VTEU investigator who has made exceptional contributions to research as it relates to the VTEU and IDCRC missions
• Early Career Investigator: A recent graduate or current participant of the IDCRC Mentoring Program who has made exceptional contributions to research as it relates to the VTEU and IDCRC missions.
• Staff STAR (Stellar Team Member Achieving Results) Award: A VTEU coordinator or administrator whose exceptional contribution has advanced and supported the quality of IDCRC supported research.
• Best Scientific Publication of the Year: An IDCRC cited publication in the last year that is considered to have had a high impact on the scientific community and/or has led to policy change.
• Leadership Group Award: An IDCRC member who has demonstrated exemplary leadership in their commitment to the IDCRC LG aims

Awards will be presented at the IDCRC Reception during the 2024 IDCRC Annual Meeting. Previous award recipients may be viewed on the Annual IDCRC Awards webpage.

Questions? Please contact Jacquelyn Manduley. 

Event

Save the Date: 2024 IDCRC Annual Meeting

Save the date! This year’s annual meeting will take place from May 1-2, 2024. We look forward to seeing you there.

Date: May 1-2, 2024
Location: In-person
5601 Fishers Lane,
Rockville, MD, 20892 

More details to follow!

VTEU Highlight 

University of Washington

Highlights from the most recent grant year were presented by all VTEUs at our 2023 Annual Meeting. This month we are featuring the University of Washington. Note, these were created by the IDCRC Leadership Operations Center and is not intended to be a comprehensive list. 

Publications

NOTE: Please include the following citation in any publications resulting from direct or indirect IDCRC support: 

"Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

View recent publications below:

• Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
• Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys
• Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country stud
• Metabolic Signatures Differentiate Immune Responses in Avian Influenza Vaccine Recipients
• Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials

News

First participant enrolled in study of IV artesunate to treat children with severe malaria in Uganda

Nadine Rouphael, MD, elected to the
American Society for Clinical Investigation (ASCI)

Robert Frenck, Jr., MD, receives
Cincinnati Pediatric Society’s 2023 Founders Award

Training

Mentee Profile: Jill Weatherhead, MD, PhD
​​​​​​​
Assistant Professor, Infectious Disease, Baylor College of Medicine

Dr. Weatherhead’s research focuses on evaluating the immunologic mechanisms of parasite induced end organ damage. She aims to develop novel diagnostic assays and therapeutic interventions that can be used clinically to combat parasitic infections globally.

Job Postings

 Infectious Diseases Research Job Openings

• Washington University in St. Louis - Research Specialist - Infectious Diseases

• University of Utah - Infectious Diseases Investigator, Tenure Track with Rank DOQ

• St. Jude Children's Research Hospital (St. Jude) - Faculty Position, Department of Infectious Diseases - Transplant

• University of Virginia - Research Scientist, Division of Infectious Diseases

• Tulane University - Infectious Diseases Physician-scientist

• University of Buffalo - Clinical Assistant, Associate, or Full Professor - Division of Infectious Diseases, Department of Pediatrics

• University of Pittsburgh - Associate/Assistant Professor of Epidemiology (Infectious Diseases)

• Cincinnati Children's Hospital Medical Center - Professor, Division Director, Infectious Diseases

• Center for Vaccine Development and Global Health (CVD) and the Institute for Genome Sciences (IGS) at the University of Maryland School of Medicine - Computational Biology/Bioinformatics (Assistant Professor or higher)

• Emory University - Post Doctoral Fellow - Emory Vaccine Center

• Baylor College of Medicine ​​​​​​- Assistant Professor at the Vaccine Research Center 

• Joint ID/EIS Fellowship

Visit the IDSA Career Center to browse other ID/HIV Medicine job postings.

Funding Opportunities

NIH Funding Opportunities Specific to COVID-19
This page contains a listing of active and expired funding opportunities.   

Notice of Special Interest (NOSI): Development of Organotypic Culture Models for Transplantation Immunology Research – Due February 5, 2024
This Notice of Special Interest (NOSI) encourages applications that focus on the development and validation of tissue-, stem-, or progenitor-cell-derived “3D” organotypic culture models (OCM) for transplantation immunology research.

NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional) – Due February 5, 2024; June 5, 2024; October  5, 2024; February 5, 2025; June 5, 225
The purpose of this funding opportunity announcement is to encourage applications for research projects within the NIAID mission. This FOA seeks to support either (a) a New Investigator (NI), an individual who has not previously competed successfully for substantial, independent funding from NIH, or (b) are an 'At-Risk' investigator, an individual who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year, from diverse backgrounds, including those from groups underrepresented in the health-related sciences.

Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed) – Due March 13, 2024
The purpose of this notice of funding opportunity (NOFO) is to invite applications from research institutions in low- and middle-income countries (LMICs) to provide senior administrators from these institutions with advanced training in the management of NIH grants. The goal is to improve oversight of NIAID grant awards and compliance with NIH funding policies and Federal research funding requirements for NIAID-supported foreign institutions in LMICs.

Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional) –  Due May 7, 2024; Due September 7, 2024
The purpose of this Notice of Funding Opportunity (NOFO) is to support applications for epidemiological and observational research projects on the long-term cardiopulmonary sequelae following treatment for tuberculosis (TB). Investigators should propose additional testing and data collection in existing cohorts of adult and/or pediatric TB participants to better characterize and understand adverse outcomes and morbidity associated with TB disease post treatment in individuals with and without HIV infection.  

NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed) – Due June 8, 2024; 2025
This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs should address scientific areas relevant to the NIAID mission including: biology and pathogenesis of infectious microbes, including HIV; host-microbe interactions; mechanisms regulating immune system development and function across the lifespan, and in response to infectious pathogens; immune dysfunction resulting in allergy, asthma, autoimmunity, immunodeficiency, or transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious and immune-mediated diseases. Each P01 application submitted to this FOA must include at least two related, synergistic research projects that share a common central theme, focus, and/or overall objective; and an administrative core. A P01 may include scientific cores, if needed for the proposed research.

International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) – Due August 2, 2024; 2025
The purpose of this Funding Opportunity Announcement (FOA) is to support applications for high-priority, regionally relevant infectious diseases research by international investigators in resource-constrained countries. Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by World Bank Classification).

NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed) – Due 30 days prior (LOI); 10/11/2024; 10/10/2025  (Full app)
The NIAID New Innovator Award supports postdoctoral and other candidates in non-independent positions or newly independent Early Stage Investigators of exceptional creativity who propose novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome.

Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission – Due January 07, 2026
The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in accepting applications that aim to understand the critical drivers of Tuberculosis (TB) transmission at the individual and population levels in high-burden settings. Applicants are encouraged to develop effective methods to measure rates of TB transmission that rely on an increased understanding of the biomedical basis of transmission and related risk factors and to develop and assess potential interventions, including low-cost and low-tech options, to prevent TB transmission.

Notice of Special Interest (NOSI): Complement in Fundamental Immunology – Due January 08, 2026
The main objective of this program is to support studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses involved in pathogenic infections, vaccination, post-infection sequelae, autoimmunity, allergy, or transplantation. The results of such studies will inform the development of vaccines or therapeutics that target complement components. The work to be encouraged includes studies of the roles of complement components (molecules and/or receptors) during immune responses.

Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine –Due January 15, 2026
The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in supporting research in the areas outlined in the  NIAID Strategic Plan For Research To Develop A Valley Fever Vaccine. The proposed research should have clear relevance to the strategic priorities defined in the strategic plan, which encompasses three major research areas: 1) address gaps in Coccidioides basic research to support the development of a vaccine; 2) develop tools and resources to support vaccine development; 3) develop and advance vaccines to prevent coccidioidomycosis.

Notice of Special Interest (NOSI): Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives – Due July 17, 2026
The purpose of this Notice of Special Interest (NOSI) is to invite applications for research on the use of targeted protein and nonprotein degradation (e.g., RNA) as it relates to the development of anti-infective strategies against viral, bacterial, parasitic, and fungal pathogens and/or their toxins (e.g., Lethal and Edema Toxins of Bacillus anthracis). Both novel monofunctional (e.g., Molecular Glues) and hetero-bi/tri-functional (e.g., PROTAC or PROTAC-like) strategies will be considered.

IDCRC Studies

IDCRC Concept Quick Stats

Communication Resources

Please submit IDCRC news to idcrc@emory.edu for inclusion in the monthly newsletter and IDCRC.org.